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Possible role of TORCH agents in 
congenital malformations in Gorgan, 
northern Islamic Republic of Iran 
M.J. Golalipour,1 B. Khodabakhshi 2 and E. Ghaemi 3  
ُّ في ةيقللخا تاهوشتلا في ايلاخلل ةمخضلما ةسويرفلاو ةينالملأا ةبصلحاو ةيدنقلا تاسوقلما لماوعل لمتحلما رودلا
 ةيملاسلإا ناريإ ةيروهجم لماش ،ناجرج
يمئاق للها تزع ،شيخبادخ زانبه ،روب ليعلك رفعج دممح
 ةيدنقلا تاسوقلما  لماوعب ىودعلا راركت ءاصقتسلا ةضرعتسلما ةيفصولا ةساردلا هذه نوثحابلا ىرجأ :ةـصلالخا
 ةنيدم في ةلاحلإل زكرم في ،ةيقلخ تاهوشتب ينباصلما نادلولا ىدل ،ايلاخلل ةمخضلما ةسويرفلاو ةينالملأا ةبصلحاو
 20  ةدم للاخ متهاهمأ نمو اديلو 64  نم مدلا تانيع  نوثحابلا ذخأ دقو .ةيملاسلإا ناريإ ةيروهجم في ناجرج
 تاهوشتب اودلو اعيضر 64   لصأ نم ةعبرأ نأ ةيلصلما تارابتخلاا ترهظأ دقو .2004و 2003  يماع  في ارهش
 سويرفلو ،)ناتلاح( ةيدنقلا تاسوقملل IgM  ةيعانلما تانيلوبولغلل ةيبايجإ دادضلأ تارايع ميهدل ،)%6( ةيقلخ
 IgM  يعانلما  ينلوبولغلا  ناك  دقو .)ةدحاو  ةلاح(  ايلاخلل  ةمخضلما  ةسويرفللو  )ةدحاو  ةلاح(  ةينالملأا ةبصلحا
 سويرفلو )تلااح 3(  ةيدنقلا تاسوقملل  نهيف ةيبايجلإا تناكو ،)%14( امأ 63  لصأ نم تاهمأ 9  ىدل ايبايجإ
  نم ةلاح يأ ىدل نوثحابلا ظحلاي لمو .)تلااح 3(  ايلاخلل ةمخضلما ةسويرفللو )تلااح 3(  ةينالملأا ةبصلحا
ًَْ
ً ّ
ً
ً
َّ
ًَّ
 .ةبحاشلا تايبلوللا لاو نياثلا طمنلا نم طيسبلا سبرلها ةسويرف تلاالحا
َّ
ABSTRACT This descriptive, cross-sectional study was carried out to explore the frequency of contami­
nation with TORCH agents in neonates with congenital malformations in a referral centre in Gorgan 
city, Islamic Republic of Iran. Blood samples were taken from 64 neonates and their mothers over a 
20-month period in 2003–04. Serologic tests showed that 4/64 infants born with congenital malforma­
tions (6%) had positive IgM antibody titres for Toxoplasma gondii (2 cases), rubella virus (1 case) and 
cytomegalovirus (1 case). IgM was positive in 9/63 mothers (14%), also for T. gondii (3 cases), rubella 
virus (3 cases) and cytomegalovirus (3 cases). No cases of herpes simplex virus type II or Treponema 
pallidum were found. 
Rôle possible des agents « TORCH » dans les malformations congénitales à Gorgan (nord de la 
République islamique d’Iran) 
RÉSUMÉ Cette étude descriptive transversale a été réalisée afin d’examiner la fréquence de la 
contamination par les agents TORCH chez les nouveau-nés présentant des malformations congénitales 
dans un centre spécialisé de Gorgan (République islamique d’Iran). Des prélèvements sanguins ont 
été effectués sur 64 nouveau-nés et leur mère pendant une période de 20 mois en 2003-2004. Les 
tests sérologiques ont montré que quatre nourrissons sur 64 nés avec des malformations congénitales 
(6 %) avaient des taux positifs d’anticorps de type IgM dirigés contre Toxoplasma gondii (2 cas), contre 
le virus de la rubéole (un cas) et contre le cytomégalovirus (un cas). Chez neuf mères sur 63 (14 %), 
les IgM étaient positifs à T. gondii (trois cas), au virus de la rubéole (trois cas) et au cytomégalovirus 
(trois cas). Aucun cas de virus de l’herpès de type 2 ou de Treponema pallidum n’a été détecté.
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Introduction 
One of the important goals in medical re-
search is determining the factors that can 
affect the health of mothers and their fe-
tuses/neonates. Congenital malformations 
are important causes of infant morbidity, 
mortality and disability, and are found in 
approximately 2%–3% of neonates [1]. 
Congenital malformations have a direct 
impact on the family, and place a financial 
burden on medical, educational and support 
services. Treatment and rehabilitation of 
children with such malformations is also 
expensive, and complete recovery is usually 
impossible [2–5]. 
The causes of congenital malformations 
are varied and few studies have evalu-
ated their etiology in neonates [4]. Previous 
studies have indicated that the prevalence 
of congenital malformation was 10.00 per 
1000 in the north of the Islamic Republic of 
Iran [5] and the prevalence of neural tube 
defect was 3.12 per 1000 in this area [6]. 
Malformations can be divided into broad 
categories, one being malformations attrib-
uted to discrete environmental factors [1,7]. 
Infectious agents, as environmental factors, 
can create intrauterine infections leading to 
birth defects, abortion and stillbirth [8,9]. 
The TORCH agents—toxoplasmosis, 
other agents, rubella virus, cytomegalovirus 
(CMV) and herpes simplex virus (HSV)— 
are the most important infectious agents that 
can cause congenital malformations. The 
infections in women are usually asympto-
matic and chronic. Prevalence varies from 
one geographical area to another [10]. The 
social and reproductive issues—pregnancy 
wastage, cost of treatment and morbid-
ity to the infant—make TORCH agents a 
major cause of concern. Many sensitive and 
specific tests are available for serological 
diagnosis of these agents. Complex ELISA 
tests for IgM antibodies against these infec-
tions are highly sensitive and specific [11]. 
There are a few reports about the role of 
infectious agents in birth defects [10–13] 
and there are different recommendations 
about screening with serology tests during 
pregnancy. This study was done to deter-
mine the frequency of contamination with 
infectious agents in neonates with congeni-
tal malformations born in a referral centre 
in Gorgan city (northern Islamic Republic 
of Iran) and their mothers. 
Methods 
This cross-sectional study was done on 
all neonates born with major congenital 
malformations during a 20-month period 
in Dezyani hospital, a referral gynaecology 
centre in Gorgan, in the north of the Islamic 
Republic of Iran during 2003–04. 
All neonates delivered alive in this hos-
pital during the study period were screened 
for congenital malformations including neu-
ral tube defects, cleft lip and palate and limb 
defects. The charts of neonates with birth 
defects were subsequently extracted for 
detailed study. Variables recorded included: 
date of birth, sex and type of malformation. 
Blood samples were taken from the 
affected neonates and their mothers after 
obtaining permission from the parents and 
the hospital directors. Then a questionnaire 
on demographic characteristics, including 
age and parents’ residence, was completed 
by interview for each case. Ethical approval 
was obtained from the Health Research 
Ethics Review Board at the University of 
Golestan, Gorgan. 
Serum was prepared from the samples 
and serologic tests were done to determine 
IgM and IgG levels against rubella virus, T. 
gondii, CMV and HSV type II with ELISA 
tests (StarFax 303 ELISA reader and kits, 
Radiom Company). The cut-off values used 
were as follows: rubella IgG positive > 20 
IU/mL, rubella IgM positive > 10 IU/mL; 
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T. gondii IgG and IgM positive > 50 IU/mL; 
CMV IgG positive > 1.1, CMV IgM posi-
tive > 15 IU/mL; HSV IgG positive > 1.1 
IU/mL, HSV IgM positive > 1.1 IU/mL 
For Treponema pallidum the rapid 
plasma reagin (RPR) test was used (Omega 
Co., Scotland). Flocculation of samples was 
considered a positive result. 
Results 
This study included 64 neonates (46% 
males) and 63 mothers (1 mother delivered 
twins). Mean and standard deviation (SD) 
of maternal and paternal ages were 26.4 (SD 
5.0) and 29.6 (SD 5.0) years respectively. 
The frequency of IgM and IgG antibod-
ies against TORCH agents in the sera of the 
neonates and mothers is shown in Tables 1 
and 2. Of the 64 neonates with birth defects, 
4 (6%) were IgM positive against TORCH 
agents: 1 for rubella virus, 2 for T. gondii
and 1 for CMV. 
Of the 63 mothers, 9 (14%) had positive 
IgM antibody titres for TORCH agents: 3 for 
T. gondii, 3 for rubella virus and 3 for CMV. 
IgM against rubella virus was observed 
in 1 neonate and 3 mothers. 
Tables 1 and 2 show that 62.5% of neo-
nates with congenital malformations and
58.7% of mothers were positive for CMV
IgG antibody. IgG antibody against T. gondii
was positive in 38.1% of mothers and 35.9% 
of neonates, but 3.2% of neonates and 4.8% 
of mothers had positive IgM antibody for
T. gondii. IgG and IgM against HSV type
II in neonates and mothers were negative in 
all cases. The RPR test for Treponema pal-
lidum was also negative in all mothers. 
Table 3 shows the distribution of posi-
tive infections according to type of defect. 
Of the 4 neonates with major malformations 
who were positive for TORCH agents, 2 
had neural tube defects, 1 had cleft plate and 
1 had limb defects. 
Discussion 
In this study, positive IgM antibody against 
TORCH agents was found in 6% of neo-
nates with congenital malformations. This is 
lower than in a study in Tabriz in the north-
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Table 1 Distribution and percentage of IgM and IgG antibody TORCH agents 
in serum samples of neonates with major congenital malformations (n = 64) 
Test Positive 
No. % 
Borderline 
No. % No. 
Negative 
% 
Herpes simplex virus 
 IgG 
 IgM 
Rubella virus 
 IgG 
 IgM 
Cytomegalovirus 
 IgG 
 IgM 
Toxoplasma gondii 
 IgG 
 IgM 
0 
0 
51 
1 
40 
1 
23 
2 
0.0 
0.0 
79.7 
1.6 
62.5 
1.6 
35.9 
3.2 
0 
0 
8 
0 
5 
0 
3 
0 
0.0 
0.0 
12.5 
0.0 
7.8 
0.0 
4.7 
0.0 
64 
64 
5 
63 
19 
63 
38 
62 
100.0 
100.0 
7.8 
98.4 
29.7 
98.4 
59.4 
96.9 
  
       
      
 
      
     
     
      
    
      
    
Table 2 Distribution and percentage of IgM and IgG antibody TORCH agents 
in serum samples of the mothers of neonates with major congenital 
malformations (n = 63) 
Test Positive 
No. % 
Borderline 
No. % 
Negative 
No. % 
Herpes simplex virus 
 IgG 
 IgM 
Rubella virus 
 IgG 
 IgM 
Cytomegalovirus 
 IgG 
 IgM 
Toxoplasma gondii 
 IgG 
 IgM 
Treponema pallidum 
 IgG 
 IgM 
0 
0 
53 
3 
37 
3 
24 
3 
0 
0 
0.0 
0.0 
84.1 
4.8 
58.7 
4.8 
38.1 
4.8 
0.0 
0.0 
0 
0 
4 
5 
7 
7 
5 
4 
0 
0 
0.0 
0.0 
6.3 
7.9 
11.1 
11.1 
7.9 
6.3 
0.0 
0.0 
63 
63 
6 
55 
19 
53 
34 
56 
63 
63 
100.0 
100.0 
9.5 
87.3 
30.2 
84.1 
54.0 
88.9 
100.0 
100.0 
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west of the Islamic Republic of Iran with 
32.5% [12]. This difference may be due to 
a higher prevalence of TORCH agents in 
pregnant mothers in Tabriz or to differences 
in sampling and study design. 
Our findings showed that 41.3% of moth-
ers were negative or borderline for antibod-
ies against CMV which means that they 
are susceptible to CMV infection during 
pregnancy. Intrauterine CMV infection and 
prenatal CMV infection occur in 9.5%–22% 
of neonates [14]. CMV infection in preg-
nancy continues to be the leading problem 
as most primary maternal infections are 
missed due to the paucity of distinct clinical 
findings. Furthermore, it seems that there is 
an increasing role of reinfection with CMV 
(that also usually passes unnoticed) as an 
important etiologic factor in congenital 
CMV [15]. 
In this study, 62.5% of neonates had 
CMV IgG antibodies. Previous studies 
showed that fetal infection occurs in 5% of 
pregnancies if primary CMV infection ex-
ists and 10%–15% of these infected fetuses 
will be delivered with important congenital 
Table 3 Distribution of type of malformations and IgM antibody in neonates and mothers 
Defect IgM-positive neonates IgM-positive mothers Total no. of 
Toxo Rubella CMV No. Toxo Rubella CMV No. anomalies 
virus virus 
Neural tube defect + – + 2 3+ 2+ 2+ 7 32 
Cleft palate – + – 1 – + + 2 14 
Limb anomaly + – – 1 – – – 0 6 
Toxo = Toxoplasma gondii; CMV = cytomegalovirus. 
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malformations [16,17]. Blackburn et al. 
reported CMV IgG antibody in up to 96% 
of pregnant women [18] but in our study 
58.7% of the mothers tested positive. 
In a study by Ebrahimpour et al. in 
Tabriz, 3.08% of neonates with congenital 
malformations were positive for CMV IgM 
antibody [12], but in the present study just 
1 case (1.6%) with congenital malforma-
tions was positive, perhaps due to a higher 
frequency of CMV infections in Tabriz. All 
mothers in the Tabriz study were positive 
for CMV IgG antibody, but in our study 
less than 60% of mothers tested positive for 
CMV IgG antibody. 
In a study in a Turkish hospital on 128 
pregnant women, 87.5% were IgG positive 
for CMV [19]. As Chiodo et al. reported, it 
is very hard to discriminate between primary 
infection and recurrent infection in preg-
nancy [20]. CMV infection may occur in the 
first trimester and cause congenital malfor-
mations, but at the time of delivery, due to 
the switching of IgM to IgG, it is difficult to 
determine the relationship between congeni-
tal malformations and CMV infection. 
Sever et al. established a matched case– 
control study to evaluate the relationship 
between congenital malformations and se-
rologic evidence of TORCH in mothers. 
However, they could not find any signifi-
cant association [21]. 
In a study in the United States of Amer-
ica, all neonates with intrauterine growth 
disorder had CMV IgM negative results 
[22]. It was concluded that serologic screen-
ing for TORCH agents is not cost-effective. 
In the present study, 38.1% of mothers and 
35.9% of neonatestested positive for IgG 
antibody against T. gondii, but 3.2% of 
neonates with congenital malformations 
and 4.8% of mothers tested positive for IgM 
antibody for T. gondii. Toxoplasmosis can 
be transmitted to the fetus up to 6 months 
after primary infection. The transmission 
rate is higher in the 3rd trimester, which can 
explain the higher rate of T. gondii IgM in 
neonates in the present study. 
Ebrahimpour et al. in Tabriz reported 
anti-Toxoplasma IgG in 100% of mothers 
and neonates [12]. This difference from our 
study is likely due to geographical differ-
ences in the prevalence of toxoplasmosis. 
Kaur et al. in India reported positive IgG for 
T. gondii in 11.6% of mothers and recom-
mended that screening tests for TORCH 
include toxoplasmosis [23]. However, an 
Irish study detected very few positive tests 
in screened samples and considered screen-
ing tests were not feasible [24]. 
Cao et al. studied TORCH serology 
in 2 groups, healthy mothers and mothers 
with abnormal conception, and reported 
Toxoplasma antibody in 16.6% and 11.1% 
respectively. They considered TORCH 
screening feasible [25]. 
No positive results for HSV type II were 
seen in our study compared with Ebrahim-
pour’s team in Tabriz, who showed positiv-
ity for HSV type I and II IgG antibodies in 
all (40 cases) of mothers [12]. This differ-
ence could be due to different laboratory 
methods and social differences. Also, Kaur 
et al. reported a prevalence of 7% for HSV
type II antibody IgG in India [23]. These 
differences need further investigation. 
Conclusion 
In this study IgM antibody against toxoplas-
mosis, rubella virus and CMV was positive 
in 14% of mothers and 6% of neonates. 
Screening tests for TORCH agents in preg-
nant mothers without a history of abnormal 
infants are not feasible, but in pregnant 
mothers with a history of abnormal con-
ception or babies, serologic testing of both 
mothers and neonates could be useful for 
detecting malformations. 
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